Aktis Oncology, Inc.

NASDAQ:AKTS

Biotechnology

Healthcare
$16.10 +0.47%

+$0.11 today

Market cap
$865.32M
Beta
1.10
P/E (TTM)
-28.7
EPS (TTM)
-$0.82
52W Low $14.72High $29.16

Volume 0.44M

Average 0.33M

AKTS Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Aktis Oncology, Inc.NASDAQ: AKTS

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization of $652K in Q1 FY2026

Q1 FY2026 depreciation & amortization was $652K. Over 3 fiscal years it compounded at +73.6% a year.

Context

  • Depreciation & amortization amounted to 35.8% of revenue in FY2025, down 70.1 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$652K-6.2% QoQ
Last fiscal yearDec 2025
$2.33M+47.9% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+47.9%——
3-year CAGR+73.6%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
2.33M USD
Year-over-year change
+47.9%
3-year CAGR
+73.6%

Depreciation & Amortization vs competitors

How AKTS compares with its peers on the latest reported figures

  • AKTS's FY2025 depreciation & amortization of $2.33M is the 4th largest of the 6 companies compared; the peer median is $3.36M.
  • Its year-over-year change of +47.9% is the highest of 6, against a peer median of -7.9%.
  • Depreciation & amortization amounts to 35.8% of revenue for AKTS, versus a peer median of 0.9%.
AKTS Competitors Peer median
Depreciation & Amortization for AKTS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGNXMacroGenics, Inc.LTM Mar 2026$6.94M -7.1%-22.5%4.4%
IMNMImmunome, Inc.LTM Sep 2026$3.76M +35.4%+67.3%—
IMCRImmunocore Holdings plcLTM Mar 2026$3.36M -17.0%-23.1%0.9%
AKTSAktis Oncology, Inc.FY2025$2.33M +47.9%+73.6%35.8%
AURAAura Biosciences, Inc.LTM Mar 2026$1.11M -7.9%-1.4%—
BCYCBicycle Therapeutics plcLTM Mar 2026$511.27K -107.2%+20.3%0.8%
Peer median (excluding AKTS) $3.36M-7.9%-1.4%0.9%

Competitors are the stored peer set for AKTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(17.93M)(28.64M)(43.98M)(63.73M)
Depreciation & Amortization445K1.12M1.58M2.33M
Deferred Income Tax0000
Stock-Based Compensation698K1.48M2.26M5.13M
Change in Working Capital(1.14M)(15K)58.98M(3.23M)
Accounts Receivables0(257K)(861K)1.03M
Inventory0000
Accounts Payables(1K)659K360K(44K)
Other Working Capital(1.14M)(417K)59.48M(4.22M)
Other Non-Cash Items(200K)(3.95M)(4.07M)(4.62M)
Operating Cash Flow(18.13M)(30M)14.76M(64.13M)
Capital Expenditures(2.31M)(3.76M)(2.86M)(9.58M)
Acquisitions (Net)0000
Purchases of Investments0(145.81M)(288.4M)(193.87M)
Sales of Investments080.69M100.86M269.42M
Other Investing Activities057K00
Investing Cash Flow(2.31M)(68.83M)(190.4M)65.96M
Debt Repayment0000
Common Stock Issued000336K
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities(151K)0(1.72M)(1.55M)
Financing Cash Flow119.98M0183.28M(1.21M)
Effect of Forex Changes0000
Net Change in Cash99.55M(98.83M)7.65M625K
Free Cash Flow(20.43M)(33.77M)11.9M(73.71M)

Aktis Oncology, Inc.

NASDAQ:AKTS

Intrinsic Alpha fair value

Locked

Current Price

$16.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.